Moderna (MRNA) – Major News
-
Moderna (MRNA) Tops Q4 EPS by $1.54, Beats on Revenue, Reaffirms COVID-19 Vax Guidance
-
Moderna (MRNA) Reports Wide Q3 Loss on $3.1B Charge, as Revenues Beat
-
Moderna (MRNA) remains comfortable with $6-8B in 2023 COVID vaccine revenue
-
Moderna (MRNA) Tops Q2 EPS by 32c
-
Moderna (MRNA) Tops Q1 EPS by 194c
-
Moderna (MRNA) Q4 Revenue Tops Consensus
-
Moderna (MRNA) Misses Q3 EPS by 228c
-
Moderna (MRNA) Announces Cancellation of Remaining 70M Dose Vaccine Order by GAVI
-
Moderna (MRNA) Sues Pfizer (PFE) and BioNTech (BNTX) for Infringing Patents Central to Moderna's Innovative mRNA Technology Platform
-
Moderna (MRNA) Tops Q2 EPS by 70c, Beats on Revenue
-
Moderna (MRNA) and EU Amend COVID-19 Vaccine Supply Agreement, Agree to Postpone Deliveries
-
Moderna (MRNA) Tops Q1 EPS by $3.37, Revenue Beats
-
Moderna (MRNA) Tops Q4 EPS by $1.39, Announces $3 billion share repurchase plan
-
Moderna (MRNA) Misses Q3 EPS by $1.35, Revenue Misses
-
Moderna (MRNA) Tops Q2 EPS by 42c
-
Moderna (MRNA) Tops Q1 EPS by 45c
-
Moderna (MRNA) Q4 Revenue Beats, Chief Medical Officer to Depart
-
Moderna (MRNA) Announces FDA Authorization of Moderna COVID-19 Vaccine in U.S.
-
Moderna (MRNA) Confirms FDA Advisory Committee Vote Supporting Emergency Use for its Vaccine Against COVID-19
-
Moderna (MRNA) COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint, 94.5% Effective
-
Moderna (MRNA) Misses Q3 EPS by 16c, Revenues Beat
-
Moderna (MRNA) Confirms Supply Agreement with U.S. Government for Initial 100 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
-
Moderna (MRNA) Tops Q2 EPS by 4c, Revenues Beat
-
Moderna (MRNA) Reports $472M Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19
-
Moderna (MRNA) Covid-19 Vaccine Produced Antibodies in Initial Study - NEJM
-
Moderna (MRNA) Announces Positive Interim Phase 1 Data for its mRNA Coronavirus Vaccine
-
Moderna (MRNA) Reports In-Line Q1 EPS
-
Moderna (MRNA) Announces $483M U.S. Agreement for COVID-19 Vaccine
-
Moderna (MRNA) said a vaccine could be available to some people, possibly including healthcare professionals, in the fall of 2020
-
Moderna (MRNA) Confirms First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
-
Moderna (MRNA) Tops Q4 EPS by 5c
-
Moderna (MRNA) Reports Q3 EPS Revenues Miss
-
Moderna (MRNA) Reports Q2 Revenues Below Consensus
-
Moderna (MRNA) Reports Q1 Revenues Below Estimates
-
Marina Biotech (MRNA) Reports Q4 Revenues Above Estimates
-
Moderna (MRNA) IPO Opens 4% Lower
-
Moderna (MRNA) Prices 26.276M Share IPO at $23/Sh
-
Marina Biotech (MRNA) to Merge with IthenaPharma
-
Marina Biotech, Inc. (MRNA) Reports Q3 Loss of $0.05
-
Marina Biotech (MRNA) Posts Wider than Expected Q1 Loss
-
Marina Biotech (MRNA) Reports In-Line Q4 EPS
-
Marina Biotech (MRNA) In Collaboration With The Debiopharm Group for RNAi-Based Bladder Cancer Therapies
-
MDRNA (MRNA) Reports Q3 Loss of $0.17
-
MDRNA (MRNA) Reports Q2 Loss of $0.21
Back to MRNA Stock Lookup